The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated MASCOT, a phase III trial to assess efficacy and safety of amlenetug for the treatment of MSA....
Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA )
Also on site :
- Blake Lively Wins Legal Battle Against Justin Baldoni
- Ax-wielding man at Pacific Beach library faces preliminary hearing
- Tony Awards draw best audience in 6 years for CBS